DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/2303
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorRocha, Amanda de Araújo-
dc.date.available2020-03-13-
dc.date.available2020-03-13T14:51:40Z-
dc.date.issued2019-03-29-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/2303-
dc.description.abstractBreast cancer can be defined as a heterogeneous disease of multifactorial character, there are a number of risk factors for breast development, including hereditary factors, hormones, age, physical inactivity, alcohol, radiation and obesity. Mutations in the BRCA1 gene are responsible for 50% of hereditary breast cancer cases. The aim of this study was to characterize a group of patients treated at the Amazonas State Oncology Control Center Foundation (FCECON) regarding hereditary breast cancer risk factors. This study was carried out at the Proteomics and Genomics Laboratory of the EU, using direct sequencing of 8 exons of the BRCA1 gene. Patients with myocardial revascularization syndrome, with family history of predisposition and risk of hormonal life. Changes in gene data have been verified in existing databases for this gene (ClinVar, BRCA Exchange and Varsome). The 4 forms of mutation that are missense mutation c.4304T> C exon 13 (16 patients), missense mutation c.4837A> G exon 16 (25 patients), frameshifth mutation c.5266dupC exon 20 (1 patient) and mutation were studied. intronic c.5277 + 48_5277 + 59dup (1 patient). Of the 53 patients studied, 26 had mutations, where only one patient had a disease-based mutation, a mutation of c.4837 A> G was frequent in 25 patients ruling out a possibility of being deleterious. As mutations have reported that studies have not yet had data on industry developments in the literature, which is particularly necessary so that they cannot have a BRCA1 gene in the Brazilian and worldwide population. Therefore, what is most important for the development of new future series is that the Brazilian knowledge pattern is mutational for high-capacity breast cancer genes such as BRCA1. Key words: Breast cancer, hereditary cancer syndrome, BRCA1.pt_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.rightsAtribuição-NãoComercial-SemDerivados 3.0 Brasil*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/br/*
dc.subjectCâncer de mama.pt_BR
dc.subjectcancer hereditário.pt_BR
dc.subjectBRCA1pt_BR
dc.titleRastreio de mutação do gene BRCA1 em pa cientes com câncer de mama atendidos em uma unidade de saúde do Estado do Amazonas / Amanda de Araújo Rocha.pt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2020-03-13T14:51:40Z-
dc.contributor.advisor-co1Benzaquem, Denise Correa-
dc.contributor.advisor-co1Latteshttp://lattes.cnpq.br/9528510380898905pt_BR
dc.contributor.advisor1Rezende, Cleiton Fantin-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/3982396993273580pt_BR
dc.contributor.referee1Rezende, Cleiton Fantin-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/3982396993273580pt_BR
dc.contributor.referee2Soares, Fernanda Rodrigues-
dc.contributor.referee3Do carmo, Edson Júnior-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/5780309549588357pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/4563871755038745pt_BR
dc.description.resumoO câncer de mama pode ser definido como uma doença heterogênea de caráter multifatorial, há uma série de fatores de risco reconhecidos para o desenvolvimento do câncer de mama, incluindo fatores hereditários, hormonais, idade, sedentarismo, álcool, radiação e obesidade. Mutações no gene BRCA1 são responsáveis por 50% dos casos de câncer de mama hereditário. O objetivo desse estudo foi caracterizar um grupo de pacientes com câncer de mama atendidos na Fundação Centro de Controle de Oncologia do Estado do Amazonas (FCECON) quanto a fatores de risco para câncer de mama hereditário. Este estudo foi realizado no Laboratório de Proteômica e Genômica da Universidade do Estado do Amazonas (UEA), utilizando sequenciamento direto de 8 éxons do gene BRCA1. Foram analisados 53 pacientes (51mulherese 2 homens) com idade variando entre 30 a 71 anos, a maioria destes pacientes nascidos no estado do Amazonas, com histórico familiar para predisposição e fator de risco hormonal. As alterações encontradas nos éxons estudados do gene foram verificadas em 3 bancos de dados online existentes para este gene (ClinVar, BRCA Exchange e Varsome). Foram identificadas o total de 4 tipos de mutações sendo elas mutação missense c.4304T>C éxon 13 (16 pacientes), mutação missense c.4837A>G éxon 16 (25 pacientes), mutação frameshifth c.5266dupC éxon 20 (1 paciente) e mutação intrônica c.5277+48_5277+59dup (1 paciente). Dos 53 pacientes estudados 26 são portadores de mutações, onde apenas uma paciente apresentou a mutação fundadora Ashkenazi c.5266dupC, mutação esta já identificada em estudos genéticos na população brasileira, a mutação c.4837A>G foi frequente em 25 pacientes descartando a possibilidade de ser deletéria. Das mutações relatadas nesse estudo duas ainda não possuem dados sobre seus mecanismos moleculares na literatura, o que torna necessário estudos complementares, para se obter melhor entendimento da consequência dessas mutaçãoes no gene BRCA1 na população brasileira e mundial. Portanto, acentua-se a importância de ampliar este estudo e estimular pesquisas futuras, para se refinar o conhecimento do padrão mutacional brasileiro para os genes de alta penetrância para o câncer de mama como o BRCA1. Palavras chave: Câncer de mama, síndrome do cancer hereditário, BRCA1.pt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPós-Graduação em Biotecnologia e Recursos Naturaispt_BR
dc.relation.referencesABREU, E. DE; KOIFMAN, S. Fatores prognósticos no câncer da mama feminina. Revista Brasileira de Cancerologia, v. 48, n. 1, p. 113–131, 2002. ACS. American Cancer Society. Disponivel em: https://www.cancer.org/ > Acesso em: 20 fev. 2019. ALVARENGA, M. et al. Contribuição do patologista cirúrgico para o diagnóstico das síndromes do câncer hereditário e avaliação dos tratamentos cirúrgicos profiláticos. Jornal Brasileiro de Patologia e Medicina Laboratorial, v. 39, n. 2, 2003. ASCO. American Society of Clinical Oncology. Disponível em: <https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer>. Acesso em: 3 mar. 2019. ASPEREN, C.J.; BROHET, R.M.; MEIJERS-HEIJBOER, E.J.; HOOGERBRUGGE, N.; VERHOEF, S.; VASEN, H.F.A.; AUSEMS, M.G.E.M.; MENKO, F.H.; GOMEZ GARCIA, E.B.; KLIJN, J.G.M. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. Journal of Medical Genetics., 42, 711–719, 2005. ABREU, E. DE; KOIFMAN, S. FATORES PROGNÓSTICOS NO CÂNCER DA MAMA FEMININA. REVISTA BRASILEIRA DE CANCEROLOGIA, V. 48, N. 1, P. 113–131, 2002. ALVARENGA, M.; COTTA, A. C.; DUFLOTH, R. M.; SCHMITT, F. C. L.; CONTRIBUIÇÃO DO PATOLOGISTA CIRÚRGICO PARA O DIAGNÓSTICO DAS SÍNDROMES DO CÂNCER HEREDITÁRIO E AVALIAÇÃO DOS TRATAMENTOS CIRÚRGICOS PROFILÁTICOS. JORNAL BRASILEIRO DE PATOLOGIA E MEDICINA LABORATORIAL, V. 39, N. 2, 2003. ASCO. AMERICAN SOCIETY OF CLINICAL ONCOLOGY. DISPONÍVEL EM: <HTTPS://WWW.ASCO.ORG/PRACTICE-GUIDELINES/QUALITY-GUIDELINES/GUIDELINES/BREAST-CANCER>. ACESSO EM: 3 MAR. 2019. BAGCI, O.; KURTGÖZ, S. AMPLIFICATION OF CELLULAR ONCOGENES IN SOLID TUMORS. NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, V. 7, N. 8, P. 341–346, 2015. BLAIR, A. B; GROOT, V. P; GEMENETZIS, G; WEI, J; CAMERON, J. L; WEISS, M. J; GOGGINS, M; WOLFGANG, C. L; YU, J. H.E. BRCA1/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 226(4):630-637, 2018. BIC. Breast cancer Information Core database. Disponível em: https://research.nhgri.nih.gov/projects/bic/Member/mutation_draw/index.cgi. Acesso em: 2 mar. 2019. BIUNNO, I.; ACETO, G.; AWADELKARIM, K. D.; MORGANO, A.; ELHAJ, A.; 56 ELTAYEB, A. E.; ABUIDRIS, D. O.; ELWALI, N. E.; SPINELLI, C.; BLASIO, P.; ROVIDA, E.; Mariani-Costantini, R. BRCA1 point mutations in premenopausal breast cancer patients from Central Sudan. Familial Cancer, 13:437–444, 2014. BOUGIE O, WEBERPALS J. I. Clinical considerations of BRCA1- and BRCA2-Mutation carriers: a review. Int J Surg Oncol, 374012, 2011. BLACKWOOD, M. A.; WEBER, B. L. BRCA1 and BRCA2: from molecular genetics to clinical medicine. Journal of Clinical Oncologyu, v. 16, n. 5, p. 1969–77, 1998. BLOOM, H. J. G.; RICHARDSON, W. W. Histological grading and prognosis of breast cancer. British journal of cancer, v. 11, n. 3, p. 359–77, 1957. BORGES-OSORIO, M. R.; ROBINSON, W. M. Genetica humana. 3ª edição, 2013. BROCA, P. P. Traité des tumeurs. Paris, P. Asselin. 1866. CARRARO, D. M.; KOIKE, M. A. A. F.; GARCIA, B. C. L.; RIBEIRO, E. H. O.; VITORIANO, A. C. K.; CARVALHO, A. F.; MOTA, L. D. C.; PUGA, R. D.; MACIEL. S. M.; MICHELLI, R. A.D.; LYRA, E. C.; Comprehensive Analysis of BRCA1, BRCA2 and TP53 Germline Mutation and Tumor Characterization: A Portrait of Early-Onset Breast Cancer in Brazil. PLoS ONE, v. 8, n. 3, p. 7–9, 2013. CARVALHO-SILVA, D. R.; SANTOS, F. R.; ROCHA, J.; PENA, S. S. J. The phylogeography of Brazilian Y-chromosome lineages. American journal of human genetics, v. 68, n. 1, p. 281–286, 2001. CASTRO, E. EELES, R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. v. 14. p. 409-414, 2012. CHERBAL, F.; SALHIA, N.; RABAH BAKOUR, R.; ADANE, S.; BOUALGA, K.; MAILLET, P. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Disease Markers, 2012. CLARK, A.S.; DOMCHEK, S.M. Clinical management of hereditary breast cancer syndromes. J Mammary Gland Biol and Neoplasia, 16(1):17–25, 2011. CORNEJO-MORENO, B. A.; URIBE-ESCAMILLA, D.; SALAMANCA-GÓMEZ, F. Breast cancer genes: Looking for BRACA???s lost brother. Israel Medical Association Journal, v. 16, n. 12, p. 787–792, 2014. DA COSTA, E. C. B.; VARGAS, F.R.; MOREIR, A. S.; LOURENÇO, J. J.; CALEFFI, M.; ASHNTON-PROLLA, P; MARTINS MOREIRA, M. A. M. Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast and ovarian cancer syndrome. Cancer Genetics and Cytogenetics,184:62-66, 2008. 57 DOMBERNOWSKY, S. L.; WEISCHER, M.; FREIBERG, J.J.; BOJESEN, S. E.; TYBJARG-HANSEN, A.; BORGE NORDESTGAARD, G. Missense Polymorphisms in BRCA1 and BRCA2 and Risk of Breast and Ovarian Cancer. Cancer Epidemiology, Biomarkers & Prevention. 2009 DELMONICO, L.; ALVES, G.; AMARAL, L. F. P. A biologia do câncer de mama e testes moleculares de prognóstico. Revista Hospital Universitário Pedro Ernesto, v. 14, n. 0, 2015. DOYLE, J.; DOYLE, J. Isolation of plant DNA from fresh tissue. Focus, v. 12, p. 13–15, 1990. DUFLOTH, R. M.; CARVALHO, S.; HEINRICH, J. K.; SHINZATO, J. Y.; SANTOS, C. C.; ZEFERINO, L. C.; SCHMITT, F. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo medical journal, v. 123, n. 4, p. 192–197, 2005. ECONOMOPOULOU, P.; DIMITRIADIS, G.; PSYRRI, A. Beyond BRCA: New hereditary breast cancer susceptibility genes. Cancer Treatment Reviews, v. 41, n. 1, p. 1–8, 2015. EISINGER, F, SOBOL, H, SERIN, D, WHORTON, J.C. Hereditary breast cancer, circa 1750. Lancet, 351:1366, 1998. ESCOBAR, K. A. Determinação de mutações e polimorfismos nos genes BRCA1 e BRCA2 em pacientes com câncer de mama com indicação para teste genético. [s.l.] Faculdade de Medicina da Universidade de São Paulo, 2011. J. C. FERNÁNDEZ-LOPEZ, J. C.; ROMERO-CÓRDOBA, S.; REBOLLAR-VEGA, R.; ALFARO-RUIZ, L. A.; JIMÉNEZ-MORALES, S.; BELTRÁN-ANAYA, F.; ARELLANO-LLAMAS, R.; CEDRO-TANDA, A.; RIOS-ROMERO, M.; RAMIREZ-FLORENCIO, M.; BAUTISTA-PIÑA, V.; DOMINGUEZ-REYES, C.; VILLEGAS-CARLOS, F.; TENORIO-TORRES, A.; HIDALGO-MIRANDA, A. Population and breast cancer patients’ analysis reveals the diversity of genomic variation of the BRCA genes in the Mexican population. Human Genomics. 2019. FOULKES, W. D. Inherited susceptibility to common cancers. N Engl J Med, 359: 2143-53, 2008. GLOBOCAN. International Agency for Research on Cancer. Disponível em: <http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.>. Acesso em: 10 fev. 2018. GOBBI, H. Classificação dos tumores da mama: atualização baseada na nova classificação da Organização Mundial da Saúde de 2012. Jornal Brasileiro de Patologia e Medicina Laboratorial, v. 48, n. 6, p. 463–474, 2012. 58 GOMES, M. C. B.; COSTA, M. M.; BOROJEVIC, R.; MONTEIRO, A. N.; VIEIRA, R.; KOIFMAN, S.; KOIFMAN, R. J.; LI, S.; ROYER, R.; ZHANG, S.; NAROD, S. A. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast cancer research and treatment, v. 103, n. 3, p. 349–53, jul. 2007. GOMES, M. C. B.; COSTA, M. M.; VIEIRA, R.; FILHO, A. G. F.; KOIFMAN, S.; KIFMAN, R. J.; SUN, P.; NAROD, S. A. Prevalência da mutação BRCA1 e BRCA2 em pacientes com câncer de mama em uma população do Rio de Janeiro, Brasil. Revista Brasileira de Oncologia Clínica, p. 24–28, 2011. HALL, J.; LEE, M.; NEWMAN, B.; MORROW, J.; ANDERSON, L.; HUEY, B; KING, M. Linkage of early-onset familial breast cancer to chromosome 17q21. Science, v. 250, n. 4988, p. 1684–1689, 1990. HALL, T. A. Bio Edit: a user-friendlybiological sequence alignment editor end analysis program for windows 95/98/NT. Nucl. Acidr. Fynp. Ser., 41: 95-98, 1999. HERMAN, S.; Varga, D.; Deissler, H. L.; Kreienberg, R.; Deissler, H. Medium-sized deletion in the BRCA1 gene: Limitations of Sanger sequencing and MLPA analyses. Genetics and Molecular Biology, v. 35, n. 1, p. 53–56, 2012. HEYWANG-KÖBRUNNER, S. H.; Schreer, I.; Heindel, W.; Katalinic, A. Imaging studies for the early detection of breast cancer. Deutsches Ärzteblatt international, v. 105, p. 541–7, 2008. HURVITZ, S.; MEAD, M. Triple-negative breast cancer. Current Opinion in Obstetrics and Gynecology, p. 1, 2015. INCA. Estimativa | 2018 Incidência de Câncer no Brasil. Rio de Janeiro: [s.n.]. KALIA, M. Biomarkers for personalized oncology: Recent advances and future challenges. Metabolism: Clinical and Experimental, v. 64, n. 3, p. S16–S21, 2015. KARAMI, F.; MEHDIPOUR, P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. BioMed research international, v. 2013, p. 928562, 2013. KESHAVARZI, F.; JAVADI, G. R.; ZEINALI, S. BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients. Familial Cancer, 11:57–67, 2012. KING, M. C; MARKS, J. H; MADELL, J. B. New York Breast Cancer Study Group. Breast and ovarian cancer, risks due to inherited mutation in BRCA1 and BRCA2. Science, 302:643–6, 2003. KEY, T. J.; VERKASALO, P. K.; BANKS, E. Reviews Epidemiology of breast cancer. Oncology, 44, n. 0, p. 133–140, 2001. 59 KOTE-JARAI, Z; LEONGAMORNLERT, D.; SAUNDERS, E. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer. v.105. p. 1230-1234, 2011. KOUROU, K.; EXARCHOS, T. P.; EXARCHOS, K. P.; KARAMOUZIS, M. V.; FOTIADIS, D. I.; Machine learning applications in cancer prognosis and prediction. Computational and Structural Biotechnology Journal, v. 13, p. 8–17, 2015. KOZAK, F. K, HALL, J. G, BAIRD, P.A. Familial breast cancer in males: a case report and review of the literature. Cancer; 58:2736-9, 1986. KUCHENBAECKER, K.B.; HOPPER, J.L.; BARNES, D.R.; PHILLIPS, K.-A.; MOOIJ, T.M.; ROOS-BLOM, M.-J.; JERVIS, S.; LEEUWEN, F.E.; MILNE, R.L.; ANDRIEU, N.; Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317, 2402–2416, 2017. LAITMAN, Y; FENG, B.J; ZAMIR, I. M; WEITZEL, J. N; DUNCAN, P; PORT, D; THIRTHAGIRI, E; TEO, S.H; FRIEDMA, E. Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations. European Journal of Human Genetics, 21, 212-216, 2013. LEHMAN, C. D. Magnetic resonance imaging in the evaluation of ductal carcinoma in situ. Journal of the National Cancer Institute - Monographs, v. 196, n. 41, p. 150–151, 2010. LI, M. M; DATTO, M; DUNCAVE, E.J; KULKARNI, S; LINDEMAN, N.I;ROY,S; TSIMBERIDOU, A. M; VNENCAK-JONES, C.L; WOLFF, D. J; YOUNES, A; KIKIFOROVA, M. N. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. Journal of Molecular Diagnostics, v. 19, n. 1, p. 4–23, 2017. LINDOR, N.M.; GUIDUGLI, L.; WANG, X.; VALLÉE, M.P.; MONTEIRO, A.N.A.; TAVTIGIAN, S.; GOLDGAR, D.E.; COUCH, F.J. A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Human Mutat, 33, 8–21, 2012. LOESCHER, L. J. The family history component of cancer genetic risk counseling. Cancer Nurse, v. 22, n. 1, p. 96–102, 1999. LOURENÇO, J. J, VARGAS, F. R, BINES J. BRCA1 mutations in Brazilian patients. Genetics Mol Biol, 27:500-4, 2004. LYNCH, H. T.; SNYDER, C.; CASEY, M. J. Hereditary ovarian and breast cancer: What have we learned. Annals of Oncology, v. 24, n. SUPPL.B, 2013. MIKI, Y.; SWENSEN, J.; SHATTUCK-EIDENS, D.; FUTREAL, P. A.; HARSHMAN, K.; TAVTIGIAN, S.; LIU, Q.; COCHRAN, C.; BENNETT, L. M. Strong Candidate for the 60 Breast and Ovarian Cancer Susceptibility Gene BRCA1. Science, v. 266, p. 66–71, 1994. MINISTÉRIO DA SAÚDE (BRASIL). Protocolos clínicos e diretrizes terapêuticas em oncologia. 1. ed. 2014. MORAN, A.; O’HARA, C.; KHAN, S.; SHACK, L.; WOODWARD, E.; MAHER, E.R.; LALLOO, F.; EVANS, D.G.R. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer , 11, 235–242, 2012. NASCIMENTO, F. B.; PITTA, M. G. R.; RÊGO, M. J. B. M. Análise dos principais métodos de diagnóstico de câncer de mama como propulsores no processo inovativo. Arquivos de medicina, 2015. NAROD, S. A.; FOULKES, W. D. BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer, v. 4, n. 9, p. 665–676, 2004. NCCN. Breast cancer. In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). [s.l: s.n.]. v. 1p. 1–209. OPAS. Organização Pan-Americana da Saúde. Disponível em: <http://www.paho.org/bra/index.php?option=com_content&view=article&id=5344:diagnostico-precoce-do-cancer-salva-vidas-e-reduz-custos-de-tratamento&Itemid=839>. Acesso em: 15 fev. 2019. OTTMAN, R, PIKE M. C, KING M. C. Practical guide for estimating risk for familial breast cancer. Lancet, 2:556-8, 1983. PALMA, G.; FRASCI, G.; CHIRICO, A.; ESPOSITO, E.; SIANI, C.; SATURNINO, C.; ARRA, C.; CILIBERTO, G.; GIORDANO, A.; D’AIUTO, M. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget, v. 6, n. 29, p. 26560–26574, 2015. PALMERO, E. I.; ALEMAR, B.; SCHÜLER-FACCINI, L.; HAINAUT, P.; MOREIRA-FILHO, C. A.; EWALD , I. P.; SANTOS, P. K.; RIBEIRO, L. I.; NETO, C. B. O.; CALVEZ-KELM, F. L.; TAVTIGIAN , S.; COSSIO, S. L.; GIUGLIANI, R.; CALEFFI, M.; ASHTON-PROLLA, P. P. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genetics and Molecular Biology, v. 39, n. 2, p. 210–222, 2016. PIETSCHMANN, A.; MEHDIPOUR, P.; ATRI, M.; HOFMANN, W.; HOSSEINI-ASL, S. S.; SIEGFRIED SCHERNECK, S.; MUNDLOS, S.; PETERS, H.; Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families. J Cancer Res Clin Oncol. 131: 552–558, 2005. PIERCE, B. A. Génetica: Um Enfoque Conceitual. 5. ed. Rio de Janeiro: [s.n.]. 61 RAKHA, E. A. Soria, D.; Green, A. R.; Lemetre, C.; Powe, D. G.; Nolan, C. C.; Garibaldi, J. M.; Ball, G.; Ellis, I. O.; Nottingham prognostic index plus (NPI+): A modern clinical decision making tool in breast cancer. British Journal of Cancer, v. 110, n. 7, p. 1688–1697, 2014. READY, K.; GUTIERREZ-BARRERA, A.M.; AMOS, C.; MERIC-BERNSTAM, F.; LU, K.; HORTOBAGYI, G.; ARUN, B. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Journal Breast, 17, 210–212. 2011. REBBECK, T. R.; MITRA, N.; WAN, F.; SINILNIKOVA, O. M.; HEALEY, S.; LESLEY, G. Consortium Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA - Journal of the American Medical Association, v. 313, n. 13, p. 1347–1361, 2015. RICH, T. A. et al. Hereditary breast cancer syndromes and genetic testing. Journal of Surgical Oncology, v. 111, n. 1, p. 66–80, 2015. RIZZOLO, P; SILVESTRI, V.; TOMMASI, S. Male breast cancer: Genetics, epigenetics, and ethical aspects. Ann Oncol. v.24. p. viii75- viii82, 2013. RODRIGUEZ, J. A.; AU, W. W. Y.; HENDERSON, B. R. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Experimental Cell Research, v. 293, n. 1, p. 14–21, fev. 2004. SAMBROOK, J.; GREEN, M. R. Molecular cloning - A Laboratory Manual. Cold Spring Harbor, v. 1, p. 1–34, 1989. SCHWEIGER, M. R. et al. The power of NGS technologies to delineate the genome organization in cancer: From mutations to structural variations and epigenetic alterations. Cancer and Metastasis Reviews, v. 30, n. 2, p. 199–210, 2011. SIEGEL, R.; NAISHADHAM, D.; JEMAL, A. Cancer statistics 2012. CA Cancer J. Clin. v.62. p.10-29, 2012. SILVA, F. C.; LISBOA, B. C. G.; FIGUEIREDO, M. C. P.; TORREZAN, G. T.; SANTOS, E. M. M.; KREPISCHI, A. C.; ROSSI, B. M.; ACHATZ, M. I.; CARRARO, D. M.; Hereditary breast and ovarian cancer: Assessment of point mutations and copy number variations in Brazilian patients. BMC Medical Genetics, v. 15, n. 1, p. 1–11, 2014. SILVA FELICIO, P. et al. Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer. Oncotarget, v. 8, n. 2, p. 2850–2862, 2017. SIMARD, J.; TONIN, P.; DUROCHER, F.; MORGAN, K.; ROMMENS, J.; GINGRAS, S.; SAMSON, C.; LEBLANC, J.F.; BÉLANGER, C.; DION, F.;- LIU, Q.; SKOLNICK, M.; GOLDGAR, D.; SHATTUCK-EIDENS, D.; LABRIE, F.; NAROD, S.A. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature 62 Genetics. 1994. SUSZYNSKA, M.; KLONOWSKA, K.; JASINSK, A. J.; KOZLOWSKI, P. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Gynecologic Oncology, 452–462, 2019. TAI, Y. C.; DOMCHEK, S.; PARMIGIANI, G. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. v. 99. P.1811-1814, 2007. TEJERINA BERNAL, A. et al. Breast imaging: How we manage diagnostic technology at a multidisciplinary breast center. Journal of Oncology, v. 2012, 2012. THOMPSON; THOMPSON. Genética Médica. In: Genética Médica. 7 ed ed. [s.l: s.n.]. p. 1–1.514. TIMOTEO, A. R. S., Identificação e caracterização molecular de mutações germinativas em indivíduos com Síndrome de Câncer de Mama e Ovário Hereditário. [s.l.] UNIVERSIDADE FEDERAL DO RIO GRANDE DO NORTE, 2016. TSAI, C. J.; SAUNA, Z. E.; KIMCHI-SARFATY, C.; AMBUDKAR, S. V.; GOTTESMAN, M. M.; NUSSINOV, R. Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. Journal of Molecular Biology. November 2008;383(2):281-291. TUNG,N. M. D.; BATTELLI, C. M. D; ALLEN, B. M. S.; KALDATE, R. M.S; BHATNAGAR, S.; BOWLES, K.; TIMMS, K.; GARBER, J.; HEROLD, C.;ELLISEN, L.; KREJDOVSKY, J.; DELEONARDIS, K.; SEDGWICK, K.;SOLTIS, K.; ROA, B.; WENSTRUP, R. J.; HARTMAN, A. R. Frequency of Mutations in Individuals With Breast Cancer Referred for BRCA1 and BRCA2 Testing Using Next-Generation Sequencing With a 25-Gene Panel. Cancer, 2015. VENKITARAMAN, A. R. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science, v. 343, n. 6178, p. 1470–1475, 2014. WALLIS, Y. et al. Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics. Acgs, n. September, p. 16, 2013. WEIGELT, B.; GEYER, F. C.; REIS-FILHO, J. S. Histological types of breast cancer: How special are they? Molecular Oncology, v. 4, n. 3, p. 192–208, 2010. WONG, S. M.; FREEDMAN, R. A.; SAGARA, Y.; AYDOGAN, F.; BARRY, W. T.; GOLSHAN, M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 2017 Mar;265(3):581-589, 2017. YADAV, B. S. Biomarkers in triple negative breast cancer: A review. World Journal of Clinical Oncology, v. 6, n. 6, p. 252, 2015. 63 YANG, M.; DU, X.; ZHANG, F.; YUAN, S. Association between BRCA1 polymorphisms rs799917 and rs1799966 and breast cancer risk: a meta-analysis. Journal of International Medical Research, 0(0) 1–8, 2019 YERUSHALMI, R.; HAYES, M. M.; GELMON, K. A. Breast carcinoma - Rare types: Review of the literature. Annals of Oncology, v. 20, n. 11, p. 1763–1770, 2009.pt_BR
dc.subject.cnpqBiotecnologiapt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - MBT Programa de Pós-Graduação em Biotecnologia e Recursos Naturais da Amazônia



Este item está licenciada sob uma Licença Creative Commons Creative Commons